Gamifant® (emapalumab-lzsg) is the first and only FDA-approved treatment for patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy.
Your journey with Gamifant starts here
Take the next step
This video can help you learn more about primary HLH and how it's treated.
This video can help you learn more about primary HLH and how it's treated.
Need more information? We're here for you. Call Gamifant Patient Services at 833-597-6530
